All NewsFDA BriefsOncology IconsSpecial ReportsThe Targeted PulseVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPivotal Practice Views with the Oncology BrothersPodcastsPrecision MedicineSpeaking Out
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CASE-BASED ROUNDTABLEPARTNERS
CME/CEClinical TrialsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Biomarker-Driven Lung Cancer
  • GIST
  • HER2 Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Small Cell Lung Cancer
  • Renal Cell Carcinoma
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CASE-BASED ROUNDTABLE
    • PARTNERS
    • SUBSCRIBE
Advertisement

Optimal Management of Stage IIIA Hodgkin's Lymphoma

home / case-based-peer-perspectives / gordon-hodgkin-lymphoma

Optimal Management of Stage IIIA Hodgkin's Lymphoma

Approaching a Case of Stage IIIa Hodgkin Lymphoma

EP. 1: Approaching a Case of Stage IIIa Hodgkin Lymphoma

October 29th 2018

Watch

Hodgkin Lymphoma: Considerations for Frontline Therapy

EP. 2: Hodgkin Lymphoma: Considerations for Frontline Therapy

October 29th 2018

Watch

Optimizing Brentuximab Vedotin Use in Hodgkin Lymphoma

EP. 3: Optimizing Brentuximab Vedotin Use in Hodgkin Lymphoma

October 29th 2018

Watch

Balancing Quality of Life and Efficacy in cHL

EP. 4: Balancing Quality of Life and Efficacy in cHL

October 29th 2018

Watch

Adding, Reducing, or Discontinuing Agents in cHL Therapy

EP. 5: Adding, Reducing, or Discontinuing Agents in cHL Therapy

October 29th 2018

Watch

Hodgkin Lymphoma: Discussing Toxicity With Patients

EP. 6: Hodgkin Lymphoma: Discussing Toxicity With Patients

October 29th 2018

Watch

Stage IIIa Hodgkin Lymphoma: Experience and Expectations

EP. 7: Stage IIIa Hodgkin Lymphoma: Experience and Expectations

October 29th 2018

Watch

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2024 MJH Life Sciences

All rights reserved.